Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Folate Transport Research.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SLC46A1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen Control | SLC46A1 Extracellular Loop Recombinant Protein Sequence Verified. High Purity (>95%), Endotoxin Controlled. Expression optimized for immunization and binding assays. |
View SLC46A1 Products |
| Gene Delivery | SLC46A1 Lentivirus Premade Particles Full-length ORF for stable cell line construction. Preserves native 12-transmembrane conformation for functional assays. |
View SLC46A1 Products |
| Benchmark Ab | Anti-SLC46A1 Recombinant Antibody Recombinant positive control derived from clinical/literature benchmarks. Sequence Verified. |
View SLC46A1 Products |
| Validator | SLC46A1 siRNA Set Target-specific knockdown pool for specificity and functional validation. |
View SLC46A1 Products |
| Related Target A | FOLR1 (Folate Receptor alpha) Primary high-affinity folate receptor. Critical for cross-selectivity screening and comparative oncology studies. |
View FOLR1 Products |
| Related Target B | SLC19A1 (Reduced Folate Carrier 1) Ubiquitous folate transporter active at physiological pH. Essential for off-target toxicity screening. |
View SLC19A1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Native 12-TM Conformation Preservation | SLC46A1 Lentiviruses deliver full-length ORF into host genomes, generating stable cell lines for flow cytometry and transport assays without protein misfolding. |
| pH-Dependent Activity Validation | Stable cell lines validated for proton-coupled folate uptake assays at tumor-microenvironment pH (5.5) vs. physiological pH (7.4). |
| Lack of Validated Controls | Sequence-verified clinical benchmark antibodies and siRNA knockdown pools included for robust assay validation. |
| Off-Target Cross-Screening | Complete assay panel including FOLR1 and SLC19A1 target reagents to confirm molecule specificity. |
Live SLC46A1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SLC46A1 (also known as PCFT - Proton-Coupled Folate Transporter) therapeutics is intensifying, with major players shifting focus from traditional small-molecule antifolates to tumor-selective antibody-drug conjugates (ADCs) and pH-sensitive folate-conjugates. As first-generation folate receptor (FOLR1)-targeting therapies reach the clinic, the next wave of R&D is targeting SLC46A1 to exploit the acidic tumor microenvironment.
Unlike FOLR1, which relies on receptor-mediated endocytosis, SLC46A1 functions optimally in low-pH conditions (pH 5.5), which are characteristic of solid tumor microenvironments. This unique physiological window allows for the development of highly selective therapies that spare healthy tissues operating at physiological pH (7.4).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antibody-Drug Conjugates (ADCs) | Academic Institutes, Biotech Startups | Colorectal Cancer, Ovarian Cancer, Solid Tumors | Internalization Assay (Need stable cell lines expressing native SLC46A1 conformation) |
| Folate-Conjugate Small Molecules | Pharmaceutical Developers | Inflammatory Bowel Disease (IBD), Folate Malabsorption | pH-Dependent Transport Assay (Need SLC46A1 Lentivirus for stable overexpressing lines) |
| Monoclonal Antibodies (mAbs) | Oncology Biotechs | Lymphomas, Solid Tumors | Selectivity Assay (Need SLC19A1 and FOLR1 panels for counter-screening) |